After graduating from Melbourne University in 2006, Will joined Sloane Robinson as an Asian Equity Analyst where he was seconded to SRH Capital LLP, a joint venture between Sloane Robinson LLP and Credit Suisse Asset Management as an assistant fund manager covering equity investment due-diligence. Having left Sloane Robinson in 2011, Will joined Somercourt Operations Limited, a private investment office, to run the investment due-diligence processes behind private equity and small cap investments, and has since held positions running the investment protocol and due-diligence processes for subsidiaries and affiliates including Lime Street Research and an independent equity research firm, Crest Equity Research Limited. Will is an investment advisor to Oxford Investment Consultants, a non-sector specific EIS technology fund advisory firm based in Oxford. Will took over management of Technikos with Julian Hirst in July 2016.
Julian manages Technikos in partnership with Will Middleton. He brings over 20 years’ experience as a corporate finance professional having worked several blue chip investment banks before joining the biotech sector. Julian graduated from Keble College, Oxford University and The Wharton School (MBA and Thouron Scholar). He began his career at Lehman Brothers in 1984, before moving to Morgan Stanley and UBS as Managing Director of European Technology Investment Banking in 1999. Julian became Head of Corporate Finance at Panmure Gordon in 2005. He is currently the Corporate Finance Director of Immunocore Ltd, a leading immune-oncology biotech company, is a Non-Executive Director of Oncimmune Group plc which was recently listed on AIM and specialises in early cancer detection.